Evdi
Evdi ingredients
| Active ingredient | Strength |
|---|---|
| Trabectedin | .05 mg/mL |
What Evdi is used for
The FDA lists the approved uses on the official label (below). In the EU, trabectedin is approved as Yondelis for:
Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Evdi
- Generic name
- Trabectedin
- Made by
- Apotex Corp.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- Alkylating Drug
- FDA approval
- New drug application (NDA) NDA220837
- On the US market since
- 2026
Official information
- Evdi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Trabectedin)
In India
- Trabectedin: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Evdi?
Evdi (Trabectedin) is a cancer medicine made by Apotex Corp., approved by the US FDA.
What are the ingredients of Evdi?
Evdi contains Trabectedin (.05 mg/mL).
Is Evdi approved in Europe?
The same active substance is approved in the EU as Yondelis.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA